Nobody has agreed on what the term means#
Leptin resistance names a real observation: people with more body fat have more leptin circulating — the hormone that is supposed to signal energy sufficiency to the brain — and it does not appear to suppress their appetite in proportion. The description is sound. What does not exist is a way to measure it in an individual, or a treatment that targets it.
That is not a fringe complaint. In 2012 the National Institutes of Health convened a workshop specifically because "the widespread use of the inadequately defined term 'leptin resistance'" was outrunning the science, aiming to produce a quantitative definition. The resulting paper concluded that the field "is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action"1. Fourteen years on, there is still no blood test, imaging marker, or challenge protocol that tells you whether a given person is leptin resistant. Any product sold to fix it is therefore selling a fix for something it cannot demonstrate you have.
What is actually observed, and the two mechanisms proposed for it#
The raw finding is not in dispute. Fat tissue makes leptin roughly in proportion to how much of it there is, so leptin runs high in obesity — the basic architecture of the two hunger hormones is covered in what ghrelin and leptin actually do. If leptin were a simple fullness brake, high levels should mean a strongly suppressed appetite. Observably, they don't.
Two mechanistic explanations dominate. The first is a delivery problem: leptin has to cross from blood into brain, and that transport appears saturable, so past a certain blood concentration more leptin does not become more brain leptin. The second is damage at the destination. In rodents, high-fat feeding produced inflammatory signaling in the hypothalamus "within 1 to 3 days," before substantial weight gain, along with reactive gliosis and markers suggesting neuron injury in the arcuate nucleus within the first week. These responses briefly subsided, then returned permanently with continued feeding — and MRI showed increased gliosis in the mediobasal hypothalamus of obese humans too3.
The timing in that study is the interesting part and is easy to skim past. The hypothalamic injury appeared before the obesity, which inverts the intuitive causal story. It does not prove the injury causes weight gain in humans — a cross-sectional MRI finding in people cannot establish sequence — but it does mean "they got fat, therefore their brain got inflamed" is not the only reading available.
The trial cited as proof is more complicated than its summary#
The standard evidence for leptin resistance is that giving obese people leptin doesn't work. The trial underneath that claim says something more specific. In a randomized, double-blind, placebo-controlled dose-escalation trial, 54 lean and 73 obese adults self-injected recombinant leptin at 0, 0.01, 0.03, 0.10, or 0.30 mg/kg daily. Weight loss increased with dose among all subjects at 4 weeks (P = .02) and among obese subjects at 24 weeks (P = .01). At 24 weeks the highest-dose obese cohort lost a mean of 7.1 kg2.
So leptin did produce dose-dependent weight loss in people with already-elevated leptin. Three caveats do the real work, and all three are in the paper:
| Detail | Value |
|---|---|
| Highest-dose cohort at 24 weeks | n = 8 |
| Mean (SD) weight change, that cohort | −7.1 (8.5) kg |
| Obese subjects' prescribed diet | −500 kcal/d deficit |
| Baseline leptin vs weight loss, week 24 | P = .76 |
The standard deviation was larger than the mean, in eight people; every obese participant was also dieting, so the leptin arm is not leptin alone; and baseline leptin concentration did not predict who responded, at 4 weeks (P = .88) or 24 (P = .76). The authors' own conclusion was carefully hedged — exogenous leptin "appears to induce weight loss in some obese subjects."
That last row is the one that bites. If leptin resistance were a straightforward dose problem, the people with the highest baseline leptin should have been the hardest to move. They weren't distinguishable. Whatever separates responders from non-responders, circulating leptin doesn't mark it — which is precisely the missing biomarker the NIH workshop was convened about.
Leptin therapy works where leptin is missing#
The contrast case is unambiguous. In nine women with lipodystrophy — a condition of severely deficient fat tissue and therefore severely low leptin — four months of recombinant leptin raised serum leptin from 1.3 ± 0.3 to 11.1 ± 2.5 ng/mL and produced a 1.9-point absolute fall in HbA1c in the eight with diabetes, a 60% drop in triglycerides, and a 28% reduction in liver volume4. Leptin replacement in congenital leptin deficiency is similarly dramatic.
The pattern across both literatures is consistent: leptin is transformative when it is absent and unremarkable when it is abundant. That asymmetry is the fact any theory of leptin resistance has to accommodate.
The live disagreement: a broken receiver, or a brake that was never fitted?#
Here the field genuinely splits, and the split is not about the data — both sides accept everything above. It is about what the data mean.
One camp reads the failure as a lesion: transport saturates, hypothalamic inflammation and gliosis degrade signaling, negative-feedback brakes inside the cell get stuck on. Under this reading, resistance is a pathology acquired along the way to obesity, and in principle repairable — which is why it attracts research money and, downstream, marketing.
The other camp reads it as a specification. Leptin's system is asymmetric by design: falling leptin is a starvation alarm that triggers a powerful defense of body mass, while rising leptin was never wired to be an off switch for eating. On this account, high leptin doing nothing is not a malfunction — it is the system operating normally at a range evolution rarely had to handle. Calling that "resistance" implies a brake that was never installed.
What separates the camps is testable, and it is the reason this matters to you rather than only to endocrinologists: the lesion model predicts that restoring leptin action produces sustained weight loss in common obesity. That prediction has been tested for a quarter-century and has not delivered a therapy. The specification model predicts exactly what we see — spectacular results in deficiency, scattered and unpredictable results in surplus. The evidence currently fits the second better, which is why leptin never became the obesity drug it was expected to be in 1995. It also explains why weight regain after loss feels asymmetric to the person experiencing it, a defense described in more detail under why the body resists a plateau and set-point theory.
Where does sleep fit? The popular version says short sleep lowers leptin and therefore induces resistance. The underlying trials do not line up that cleanly — pooled experimental data has leptin moving up under sleep deprivation, not down, and the full audit of sleep's appetite hormones walks through why the direction keeps flipping. Short sleep reliably changes what people eat; it has not been shown to induce anything resembling clinical leptin resistance.
What to do with the concept#
Treat it as a description of a phenomenon, not a diagnosis you have. Three consequences follow. Nothing sold as a leptin supplement contains usable leptin — it is a protein and would be digested. No "leptin reset" protocol can show it worked, because there is no accepted measure of leptin action to move1. And a stalled scale has ordinary explanations worth exhausting first, which is the ground covered in why the scale stops moving.
The useful takeaway from this literature is not a tactic. It's a recalibration: the reason appetite feels harder to override as you lose weight is not a personal failure of resolve, and it is not a hormone you can buy back.
FAQ#
Can leptin resistance be reversed?#
There is no accepted way to measure it, so there is no way to demonstrate reversal1. Weight loss does lower circulating leptin and improve several related metabolic markers, but that shows the system tracking body fat, not a resistance state being cured.
If people with obesity have high leptin, why doesn't it stop them eating?#
Two explanations compete: saturated transport into the brain plus hypothalamic inflammation degrading the signal, or the simpler possibility that rising leptin was never an appetite brake in the first place — the hormone's strong effects are on the way down, not the way up. The clinical record, where leptin therapy transforms deficiency and does little in surplus, fits the second reading more comfortably.
Why does leptin therapy work for lipodystrophy but not for common obesity?#
Because lipodystrophy is genuine leptin deficiency. Replacement took serum leptin from 1.3 to 11.1 ng/mL and cut HbA1c by 1.9 points, triglycerides by 60%, and liver volume by 28%4. In common obesity leptin is already high, and adding more has produced only inconsistent, unpredictable weight loss.
Sources#
- Myers MG Jr, Heymsfield SB, Haft C, et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metabolism. 2012;15(2):150-6.
- Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-75.
- Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. Journal of Clinical Investigation. 2012;122(1):153-62.
- Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine. 2002;346(8):570-8.
- Lin J, Jiang Y, Wang G, et al. Associations of short sleep duration with appetite-regulating hormones and adipokines: A systematic review and meta-analysis. Obesity Reviews. 2020;21(11):e13051.
